Daniel Victor Ortigoza։ Lipoprotein(a) Levels Predict Long-Term Cardiovascular Risk in Women
Daniel Victor Ortigoza, 2nd Vice President of the Cardio-Oncology Committee at the Argentine Federation of Cardiology and President of the Arrhythmias and Electrophysiology Committee of the Argentine Federation of Cardiology, shared a post on LinkedIn about a recent article by Tybjærg Nordestgaard et al, published in JAMA Cardiology:
”Thirty-Year Risk of Cardiovascular Disease Among Healthy Women According to Clinical Thresholds of Lipoprotein(a). Ask Tybjærg Nordestgaard et al.
Lipoprotein(a) (LP(a) levels are known to be genetically determined, and elevated levels are (for now) an independent and unmodifiable risk factor for cardiovascular disease (CVD).
A 30-year prospective follow-up study was conducted in healthy women, primarily of European descent, comparing baseline LP(a) levels, clinical thresholds, LP(a) percentiles, and a specific genotype to establish the probability of developing CVD.
Figure 1. Restricted Cubic Spline Curves of 30-Year Hazard Ratios (HRs) for Major Cardiovascular Events (A), Coronary Heart Disease (B), Ischemic Stroke (C), and Cardiovascular Death (D)
- On the X-axis (baseline levels), analyze LP(a) levels; on the Y-axis, analyze HR (>1 => Risk). On the Y-axis, Graph A: HR for MACE, B: CHD, C: Stroke and D: Death.
- Color zone: Lp(a) levels, green: LP(a) < 10, blue < 30, etc.
- Vertical dotted lines indicating different percentiles.
- The gray band represents the HR width; the narrower the band, the greater the accuracy of the data.
- ight vertical line: Density percentage: referring to the LP (a) with respect to the total population under study.
Interpretation of the graph:
- In CVD the strongest associated risk is obtained with LP ( a) > 150mg/dl ( red) ( HR=2.5)
- In MACE the risk associated with LP ( a) > 100 mg/dl ( HR: 1.8)
- It carries moderate risks in stroke and cardiac death.
- Only women with Lp(a) levels > 30 mg/dl or above the 75th percentile were associated with major cardiovascular disease.”
Title: Thirty-Year Risk of Cardiovascular Disease Among Healthy Women According to Clinical Thresholds of Lipoprotein(a)
Authors: Tybjærg Nordestgaard, Daniel I. Chasman, Vinayaga Moorthy, Jordan M. Kraaijenhof, Nancy R. Cook, I-Min Lee, Julie E. Buring, Paul M. Ridker
Read the Full Article on JAMA Cardiology․

Stay updated on all scientific advances with Hemostasis Today.
-
May 29, 2026, 09:53Yassin Taher: Recognizing Clonal Eosinophilic Disorders in Pediatric Hypereosinophilic Syndrome
-
May 29, 2026, 09:52Sergio Emanuel Kaiser: Ruvonoflast and a New Anti-Inflammatory Strategy for Residual Cardiovascular Risk
-
May 29, 2026, 09:50Maria Symiakaki: Advancing Cardiovascular Prevention at the 2026 Congress of the European Atherosclerosis Society
-
May 29, 2026, 09:37Katie Baca-Motes: What Can Menstrual Cycle Physiology Tell Us About Health Beyond Reproduction?
-
May 29, 2026, 09:35Torben Boelk: Bringing Plasma Donation to the Heart of Leipzig
-
May 29, 2026, 04:37Josefin Ahnström: How Andexanet Alfa Impacts TFPIα Function
-
May 29, 2026, 03:19Building Safer Systems for Anticoagulation Management – ISTH
-
May 29, 2026, 03:07Early Diagnosis Can Change the Lives of Women With Haemophilia – EHC
-
May 29, 2026, 02:41Ifeanyichukwu Ifechidere: The Biggest DOAC Myth in Coagulation – ‘No Monitoring Required’